# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Roth MKM analyst Philip Shen reiterates Bio-Path Hldgs (NASDAQ:BPTH) with a Buy and maintains $20 price target.
Peter H. Nielsen, President and Chief Executive Officer of Bio-Path, said, "With the increased clinical data that we have g...
Bio-Path Holdings shares are trading higher Friday after the company announced interim results from its Phase 2 study of prexig...
ADBE: 16% | Adobe shares are trading higher following better-than-expected Q2 earnings and strong guidance. BPTH: 46% | Bio-Pa...
The company presented interim results from the Company's Phase 2 study of prexigebersen (BP1001) in combination with decita...
Bio-Path Holdings, Inc. (NASDAQ:BPTH) ("Bio-Path" or the "Company"), a biotechnology company leveraging its pro...